Glass House Brands announced a collaboration with the University of California, Berkeley, to explore hemp-related research, including novel medicinal product development, identification and improvement of hemp genetics, market analysis, supply chain sustainability, and AI automation for cultivation and production.
In addition, the collaboration aims to evaluate data-driven and evidence-based approaches to hemp policy and regulation, with the aim of reducing uncertainty for California hemp growers. This collaboration will explore potential drug development research opportunities targeting coronaviruses, pain, sleep, inflammation, and cirrhosis.
In 2024, Glass House obtained a hemp license and has been actively growing and testing hemp on an R&D basis. Within the Company's dedicated hemp R&D greenhouse, Glass House has the capacity to produce up to 240,000 pounds of biomass annually.
"We are excited to work with UC Berkeley as we continue to evaluate our long-term hemp strategy. This is the first collaboration of its kind in this industry, and Berkeley has a successful history of assisting industry stakeholders to find innovative and sustainable solutions to environmental issues. We are confident that through this agreement, we will be better positioned to navigate the local and national legislative uncertainty for the hemp industry as we prepare to scale the business into the future," said Kyle Kazan, Co-Founder, Chairman and CEO of Glass House Brands.
Orrin Devinsky, MD, Glass House's Medical and Science Advisor to the Board of Directors and a Professor of Neurology, Neuroscience and Psychiatry, who was the lead investigator in the studies on cannabidiol leading to FDA approval said, "As a long-time proponent of cannabinoids for treatments, I'm excited to collaborate with the research faculty at UC Berkeley to explore the development of new treatments to improve the quality of life for many with disabling disorders."
For more information:
Glass House Brands
info@glasshousebrands.com
glasshousebrands.com/